Avicanna | A Leader in Biopharmaceutical Advancement

Driving Biopharmaceutical Advancements of Naturally Derived and Evidence Based Products

Who We Are

Avicanna is a Canadian international commercial-stage biopharmaceutical company

Focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across five market segments: MyMedi.ca Medical Cannabis Care Portal, Medical Cannabis & Wellness Products, Cosmetic & Skincare, Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (API)

Corporate Overview

An International Biopharmaceutical Strategy

Five active business pillars – Medical cannabis products, pharmacy platform, cosmetics, active pharmaceutical ingredients (API) and pharmaceutical pipeline

Addressing the global market – International footprint with completed transactions in 20+ countries

Established USDA organic certified vertical integration infrastructure – in Santa Marta, Colombia

Leading Scientific Platform and Intellectual Property Portfolio

Research collaborations with leading academic and clinical institutions

Proprietary and indication specific pharmaceutical pipeline

Record financial performance during Q3-23 (6.3M revenue)

30 + commercialize stage proprietary SKUs- From R&D to international commercial channels and 131 Canadian listings

Intellectual Property and Brands Owned by Avicanna

Medical Cannabis and Wellness Products – Commercial

Medical Cannabis Pharmacy Platform – Launched August

2023 Cosmetics and Skincare – Commercial

Pharmaceutical Pipeline – In development and registration stages

Active Pharmaceutical Ingredients – Commercial

Commercial Pillars and Portfolio

Avicanna’s scientific platform has produced 30+ commercial and proprietary formulations & products as well as a pharmacy platform

Including cosmetics, medical cannabis, pharmaceuticals in addition to its medical pharmacy platform and raw material business unit across international markets.

Commercial Stage
Medical Cannabis
Pharmacy Platform

Commercial Stage
Medical Cannabis & Wellness Products
Pharmacy Platform

Commercial Stage
CBD Cosmetics and Skincare

In Development and Registration Stage
Pharmaceutical Pipeline

Commercial Stage
Active Pharmaceutical Ingredients

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano-particle formulations.

30+

Proprietary Commercial Products

10+

Scientists

Canadian Government Research Grants Awarded Since 2020

Pending Patents

Health Canada Cannabis
Research Licenses to Avicanna
or Institutional Collaborators

World-class Institutional Collaborations

R&D and Clinical Partnerships Over the Past 6 Years

World-class Institutional Collaborations

20+ R&D, pre-clinical studies and research collaborations with Canada’s leading institutions and thought leaders since 2017

Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.